Amgen Inc.
AMG.DE
Deutsche Börse318.15
EUR
-8.70
- -
Amgen Inc.
AMG.DE
(Deutsche Börse)
Recent
price
318.15
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Amgen Inc. discovers, develops, manufactures and markets human therapeutics worldwide, focusing on biotechnology medicines for oncology, inflammation, general medicine, rare diseases and cardiovascular conditions. The company offers Prolia and Xgeva (denosumab) for osteoporosis and bone diseases; Enbrel (etanercept) for autoimmune diseases including rheumatoid arthritis, psoriatic arthritis and plaque psoriasis; Repatha (evolocumab) for hyperlipidemia; Otezla (apremilast) for psoriasis and psoriatic arthritis; Tepezza (teprotumumab) for Graves' ophthalmopathy; Evenity (romosozumab) for osteoporosis; Kyprolis (carfilzomib) for multiple myeloma; Nplate (romiplostim) for thrombocytopenia; Aranesp (darbepoetin alfa) for anemia; Neulasta (pegfilgrastim) and Neupogen (filgrastim) for neutropenia; Lumakras (sotorasib) for KRAS G12C-mutated non-small cell lung cancer; Tezspire (tezepelumab) for severe asthma and chronic rhinosinusitis with nasal polyps; biosimilars including Amjevita (adalimumab-atto), Mvasi (bevacizumab-awwb), Kanjinti (trastuzumab-anns), Riabni (rituximab-arrx) and others; and additional products such as Aimovig (erenumab-aooe) for migraine, Vectibix (panitumumab) for colorectal cancer, Blincyto (blinatumomab) for acute lymphoblastic leukemia, Imlygic (talimogene laherparepvec) for melanoma, Parsabiv (etelcalcetide) for secondary hyperparathyroidism, Sensipar (cinacalcet) for hyperparathyroidism, Uplizna (inebilizumab) for neuromyelitis optica spectrum disorder, Krystexxa (pegloticase) for chronic gout, Tavneos (avacopan) for vasculitis, and Corlanor (ivabradine) for heart failure. Amgen serves healthcare providers, wholesalers and patients globally, with approximately 80% of revenues from U.S. sales to major distributors including McKesson Corporation, Cencora and Cardinal Health. Founded in 1980 and headquartered in Thousand Oaks, California, the company operates manufacturing facilities in Puerto Rico, Ireland, Singapore, Rhode Island, Ohio, North Carolina and elsewhere, employing around 28,000 people across approximately 100 countries. Recent developments include a $600 million investment in a new research center in Thousand Oaks announced in September 2025; a $650 million expansion of U.S. manufacturing capabilities; a $900 million expansion of its New Albany, Ohio facility in April 2025; a $1 billion second manufacturing plant in Holly Springs, North Carolina announced in late 2024; Horizon Therapeutics plc acquisition for $27.8 billion in October 2023 adding rare disease assets including Tepezza, Krystexxa and Uplizna; ChemoCentryx acquisition for $3.7 billion in October 2022 adding Tavneos; approvals and positive data for Tezspire in chronic rhinosinusitis with nasal polyps in March 2025 and advancements in MariTide anti-obesity candidate with late-stage trials started in March 2025; and Royalty Pharma's acquisition of a royalty interest in Imdelltra from a partner in August 2025.